Boston Therapeutics Announces the North America Branding of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Boston Therapeutics Announces the North America Branding of sugardown(R): A New Natural Product That Helps Maintain Healthy Blood Sugar Levels

MANCHESTER, NH--(Marketwired - Nov 3, 2014) - Boston Therapeutics, Inc. ( OTCQB : BTHE ) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to manage post meal blood glucose levels, announced that Benchworks SD, LLC launched the branding of sugardown ® in North America. sugardown ® is a new natural dietary supplement product that helps people maintain healthy blood sugar levels. sugardown ® is the first chewable tablet of its kind. It was designed for people who are committed to a balanced diet and exercise to help keep their blood sugar levels healthy.

According to statistics published by the Center for Disease Control, there are 86 million people in the United States who have elevated blood glucose levels. These people may benefit by adding sugardown ® to their diet and exercise regimens. According to the International Diabetes Federation, there are 382 million people worldwide living with elevated blood sugar and that number is projected to increase to 592 million by 2035.

Boston Therapeutics' marketing plan for sugardown ® is to out-license marketing rights to strategic partners in their jurisdictions of expertise. The Company entered into an agreement with Advance Pharmaceutical Co. Ltd. (APC), our Hong Kong-based strategic partner to develop markets for sugardown ® in Hong Kong, China and Macau. This year to date, the Company has sold more than 20,000 bottles of sugardown ® to APC to test the Asian market. As part of the plan to increase sales, the Company recently entered into a strategic marketing collaboration with Benchworks SD, LLC, a leading branding and marketing agency, aimed at driving brand awareness and growing sales of sugardown ® among the large pre-diabetic population in North America.

The main ingredient in sugardown ® is made from naturally occurring plant-based mannans (galactomannans) that when combined with a healthy lifestyle and diet have the ability to regulate digestive enzymes which in turn promotes healthy digestion, optimal sugar absorption and supports healthy postprandial glucose levels.

The unique chewable tablet formulation works by blocking digestive enzymes starting in the mouth and promoting healthy digestion and optimal sugar absorption.

Kristen Kim, a 47-year old woman from San Jose, California, said that what ultimately sold her on the idea of trying sugardown ® was the impressive science behind the product, which was formulated by one of the world's leading complex carbohydrate scientists. "I read everything on the sugardown ® web site and was impressed that the product was a result of about 30 years of research, development, and testing. I also liked that it was a 'dietary supplement' and not a prescription medication."

Kristen continued, saying, "I usually take two sugardown ® tablets before meals, both at home and at restaurants. I always have a full bottle in my tote bag."

David Platt, Ph.D., CEO of Boston Therapeutics, manufacturer of sugardown ® , commented, saying, "As an inventor of sugardown ® , knowing that we have a natural dietary supplement that can help make a difference in people's lives is very exciting. People who want to maintain a healthy blood sugar level want some options in their life: a little freedom to choose, and that is what sugardown ® is all about."

sugardown ® is available in a bottle of 60 tablets or a convenient 10-tablet tube. For more information, visit sugardown ® on Facebook . To order, visit www.sugardown.com.

About Benchworks Benchworks LLC, based in Chestertown, Maryland, specializes in branding and positioning products by developing marketing promotions, product launches and online solutions for corporate clients ranging from mid-sized firms to Fortune 500 companies. Its client roster includes leading life science companies such as Pfizer Pharmaceuticals, Shire Pharmaceuticals, and Noven Pharmaceuticals, as well as other industry leaders such as Coca-Cola, Chrysler and CB Richard Ellis Inc. Additional information is available at www.benchworks.com .

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, ( OTCQB : BTHE ) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases. Additional information is available at www.bostonti.com .

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of any of our future drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in any subsequent drug trial could delay obtaining meaningful results from Phase II studies and/or preparing for Phase III studies with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from our approved products. Plans regarding development, approval and marketing of any of our compounds, including BTI-320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

© Boston Therapeutics, Inc. All rights reserved.

Contact: Boston Therapeutics, Inc. Anthony Squeglia Chief Financial Officer Phone: 603-935-9799 Email: anthony.squeglia@bostonti.com www.bostonti.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 21

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 66

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Corner Bakery Bets on Holiday Catering Convenience

Updated Category News Views 150

A $50 carrot on a $350 catering tab tells you exactly where Corner Bakery sees the holiday battlefield: not in one lonely cookie sale, but in the larger group order that can make a restaurant’s day. The chain is pushing holiday catering through November and December, pairing that discount with bakery trays, meals for groups and a promise to handle delivery setup. It is...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 7

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 135

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 95

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 38

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 180

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 65

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 110

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading

Top 5 Most Recently Viewed Articles

Pharvaris Shares Promising Data on Deucrictibant Efficacy

Updated Category News Views 186

Pharvaris Highlights Clinical Progress in HAE Treatment At the recent AAAAI/WAO Joint Congress, Pharvaris presented compelling long-term clinical data supporting the use of deucrictibant, a novel oral treatment for hereditary angioedema (HAE). This data underscores the drug's potential to not only prevent but also effectively address HAE attacks, offering hope to those...

Continue Reading
First Horizon Opens New Banking Center Celebrating Local Pride

Updated Category News Views 349

First Horizon Unveils New Banking Center with Appalachian Spirit First Horizon Bank (NYSE: FHN) proudly celebrated the grand opening of its newly refreshed banking center. The location pays tribute to the vibrant Appalachian State community, showcasing a striking theme that reflects its strong ties with Appalachian State University and its athletics. This celebration...

Continue Reading
Understanding Namodenoson's Role in Liver Cancer and Beyond

Updated Category News Views 243

Innovative Research on Namodenoson’s Impact in Liver Cancer Therapy Namodenoson, developed by Can-Fite BioPharma Ltd., is making waves in the medical community as a promising candidate for liver cancer treatment. Unlike traditional chemotherapy, which often harms healthy cells, Namodenoson is lauded for its protective qualities towards normal body systems. Published...

Continue Reading
Geotab Enhances Public Sector Solutions with Technological Advancements

Updated Category News Views 147

Geotab Enhances Public Sector Solutions with Technological Advancements Geotab Inc., a leader in connected vehicle solutions and asset management, has taken a major step forward in serving the public sector by expanding its cooperative purchasing contracts with Sourcewell and Canoe Procurement Group. This expansion introduces four cutting-edge solutions aimed at enhancing...

Continue Reading
Dun & Bradstreet Earns TRUSTe Certification for Responsible AI

Updated Category News Views 351

Dun & Bradstreet Achieves TRUSTe Responsible AI Certification Dun & Bradstreet (NYSE:DNB), recognized globally as a leading provider of business decisioning data and analytics, has been awarded the TRUSTe Responsible AI Certification. This certification signifies the company’s commitment to ethical and responsible governance in the realm of artificial intelligence (AI)....

Continue Reading